Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies

NCT05274451 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT05274451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05274451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2022
Completion date
November 27, 2024
Enrollment
57 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced lung carcinoma, endometrial cancer, endometrioid tumor, fallopian tube cancer, high grade serous carcinoma, non small cell lung cancer, non small cell lung cancer metastatic, non-small cell carcinoma of lung, tnm stage 4, non-small cell lung cancer, nsclc, nsclc stage iv, nsclc, recurrent, ovarian cancer, ovarian epithelial cancer, platinum-resistant ovarian cancer, primary peritoneal carcinoma, recurrent breast cancer, recurrent nsclc, relapse/recurrence, relapsed cancer, tnbc - triple-negative breast cancer, triple negative breast cancer